Time to Be Bold: Unifying Global Targets to Accelerate Global Action on AMR

Time to Be Bold: Unifying Global Targets to Accelerate Global Action on AMR

Date: May 23, 2024
Time: 2-3pm CEST / 8-9 AM EDT

Antimicrobial resistance (AMR) kills and debilitates millions of people annually and turns back progress on the UN Sustainable Development Goals (SDGs), particularly in global health, food safety and security, economic growth, poverty alleviation, and the environment. 

This year’s United Nations General Assembly (UNGA) High-level Meeting on AMR provides an opportunity to generate political and public support for meaningful global action on AMR. While many technical targets have been proposed to mitigate AMR, it is important that these initiatives be spearheaded by bold, unifying global targets that:

  • Engage public and political support globally.
  • Easily communicate progress on AMR mitigation. 
  • Use a One Health (human, animal and planetary health) approach. 
  • Focus on equity and prevention. 

Join us for a timely discussion on why unifying global targets on AMR are needed, what a unifying global target might look like, and what the implications are for both the human and animal health sectors.

This webinar will be recorded and shared with registrants. If you require support to cover data accessibility costs, please contact, contact@globalstrategylab.org.


Dr. Mathieu Poirier, Co-Director, Global Strategy Lab 

Dr. Poirier is the York Research Chair (Tier II) in Global Health Equity, and Assistant Professor of Social Epidemiology at the School of Global Health at York University. As Research Director for Global Legal Epidemiology with GSL, Dr. Poirier has led evaluations of global tobacco use and the Framework Convention on Tobacco Control (FCTC) published in the BMJ and Tobacco Control, while his global health equity research has been published in Social Science & Medicine, the Bulletin of the World Health Organization, and Social Indicators Research.

Dr. Poirier is a member of the WHO Collaborating Centre on the Global Governance of Antimicrobial Resistance, has worked throughout Latin America and the Caribbean, and has previously directed vector-borne disease research for the University of Notre Dame Haiti Program.

Dr. Masika Sophie, Global Health Policy Manager, World Federation for Animals

Dr. Masika Sophie is a highly accomplished Veterinarian and Epidemiologist. Her professional focus has been to demonstrate the value of One Health in system
strengthening to tackle complex health policy challenges.

She has vast experience in diverse multi-partner engagement with NGOs, intergovernmental organizations, Member States, and United Nations (UN) agencies through international policy advocacy and in coordinating multiple projects at all levels.

As the Global Health Policy Manager at the World Federation of Animals (WFA), Dr. Sophie provides invaluable insights and leadership in formulating a comprehensive global strategy to mitigate health risks.

Dr. Sujith Chandy, Executive Director, International Centre for Antimicrobial Resistance (ICARS)

Prior to his appointment as Executive Director at ICARS, Dr. Chandy was a Senior Professor of Pharmacology at Christian Medical College (CMC), Vellore, India and Director of ReAct Asia Pacific. He is currently a member of the WHO Strategic and Technical Advisory Group on AMR.

At ICARS, his team works with LMICs globally to codevelop contextual cost-effective solutions for one health issues using intervention and implementation research. Dr.
Chandy’s interests include global health, medicine safety, medicine management and pharmaceutical ethics. His passion however is to focus on tackling AMR through the
appropriate use of antibiotics and other relevant strategies.


Jeremy Knox, Head of Policy, Infectious Disease, Wellcome Trust 

Jeremy Knox leads Wellcome’s policy activities across its infectious disease challenge area. He is responsible for shaping and delivering against our policy goals on issues such as pandemic preparedness, vaccines, drug-resistant infections and disease surveillance.

Within Wellcome, he provides a bridging point between our Policy team and colleagues managing our research activities and investments in infectious diseases. He also works extensively with external partners who share Wellcome’s interests in this space – across academia, civil society, international organizations, and the private sector.

Before joining Wellcome in 2017, he spent much of his career working for the UK government in policy roles dealing with public and global health and emergency preparedness.